NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Akiram Therapeutics

Akiram Therapeutics

Private
UppsalaHealthcare & Life Scienceshttps://akiramtherapeutics.se/

Last Round

Grant

Nov 24, 2023

Est. Valuation

$12.31M

Total Funding Raised

$570,000

Company Overview

Akiram Therapeutics is a biotechnology company that develops innovative and targeted molecular radiotherapy for patients with incurable cancer.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine, Clinical Trials

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

targeted radioimmunotherapyradiopharmaceuticalsprecision medicinetheranosticsLutetium-177solid tumor treatmentantibody drug conjugateADCCD44v6oncology biotechclinical-stage biotechmetastatic cancer therapydrug developmentorphan drug

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Akiram Therapeutics Comparables

Compare Akiram Therapeutics with similar companies based on industry and business-model similarity.

Akiram Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
PreTT ApS
90%
Precirix
86%
Ariceum Therapeutics
82%

Akiram Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
GrantNov 24, 2023
VC RoundJan 12, 2023

Key People

Founding team and executive leadership

Anja Lundgren Mortensen

Chief Technology Officer

Executive Team

Akiram Therapeutics Investors

Notable investors and investment history

Akiram Therapeutics investors
InvestorRounds
Phase2Phase BiopharmaVC Round
ScietyVC Round
3T InvestVC Round
Erling-Persson FoundationGrant
Linc ABVC Round

Market signals

Structured signals derived from secondary market and firmographic data.

  • Oct 4, 2025

    Attending EANM Congress 2025 in Barcelona from October 4-8.

  • Apr 3, 2025

    Partnered with PreTT and TetraKit Technologies on targeted radiotherapy.

Akiram Therapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Akiram Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Akiram Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersUppsala
Employee Range6
Year Founded2021
Last FundingNov 24, 2023

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.